Lubna Hossain
Lubna Hossain
4-10, South St, Level-3, Cancer Research Laboratory,
St George Hospital,
Kogarah,NSW-2217Australia
Mobile: +61 433817231
Contact: 02 91132973
Email z3381954@student.unsw.edu.au
Nationality: Citizen of Australia
Current Status:
PhD student (3rd year), St George Clinical School, University of New South Wales, Sydney, Australia. Involved in a project ‘Formulation and evaluation of albendazole loaded albumin nanoparticles for the treatment of ovarian cancer’ collaborated with Centre for Advanced Macromolecular Design, Department of Chemical Engineering and Department of Surgery, St George hospital, UNSW, Australia.
Educational Qualification
Doctor of Philosophy in medicine, University of New South Wales, Australia Expected fall 2014.
Master of Pharmacy, Jahangirnagar University, Savar, Dhaka,Bangladesh
Bachelor of Pharmacy, Jahangirnagar University, Savar, Dhaka, Bangladesh
Research Experience
Centre for advanced macromolecular design (CAMD), Department of Chemical Engineering, UNSW; Developing a versatile drug delivery system for albendazole (hydrophobic drug). Aim to prepare biodegradable polymer albumin drug carrier system. My research focus is to prepare the albendazole lodaded albumin nanoparticles and characterization and determination of loading of the drug into the particle and finally emphasis on to the release characteristic of the drug.2011-2012
Cancer Research Laboratory, St George Hospital; Measurement of cytotoxicity of albendazole-albumin complex in in-vitro ovarian cell culture model. A comparative study between ovarian cancer cells and normal ovarian cells. Nanoparticle internalization study into the cells by using laser scanning microscopy and also performed FACS analysis to quantitatively measure the cellular uptake of nanoparticles. 2012-2013
Animal handling experience in St George Hospital; Experience in animal handling to run the project to see the in-vivo efficacy study of nab-albendazole in ovcar-3 xenograft tumor model in intraperitoneal administration of drug. Participated two animal project 2012-2013
Determination of albendazole-albumin efficacy in nude mice bearing intraperitoneal
ovarian cancer Effect of nanoparticle size of albumin bound albendazole (nab-ABZ)
on the anti-tumour activity in OVCAR-3 tumor-bearing nude mice
Work Experience
Worked as a quality Assurance Officer in Lipa Pharmaceuticals Ltd ( Largest contract manufacturer of complementary medicine in Australia) 2007- 2011
Worked as a QA/Regulatory affairs Officer in GMP Pharmaceuticals Ltd, Giraween, Sydney, Australia from 2006 to 2007
Worked as a QA/AC Officer in healthcare Pharmaceuticals Ltd, Rajendrapur, Bangladesh, (Licensee of Hoffmann-L Roche, Basel, Switzerland) from 2002 to 2005
Worked as a Production Officer, Novartis Bangladesh Ltd, Tongi, Bangladesh from 1999 to 2002
Conference attended
International Nanomedicine Conference in Sydney, Australia. 1-3 July, 2013
(Oral presentation)
CLINAM 2013 (The European Summit for Clinical Nanomedicine, Basel , Switzerland) 23-26 Jun, 2013
(Poster presentation and selected for small talk session)
Lowy Cancer Symposium, UNSW, Australia, May 2013 (Poster presentation)
Drug Delivery Australia (DDA, 2012) Melbourne, Australia, Nov, 2012
(poster received honorary top 10 out of 80 posters selected for oral presentation)
International Nanomedicine Conference, Sydney, Australia July, 2011 and 2012
St George Sutherland Symposium, October, 2011 & 2012 (Poster presentation)
Award/Scholarship
APA (Australian Postgraduate Award) (2011-2013) for conducting research in formulation and evaluation of anticancer drug in ovarian Cancer.
Travel Scholarship (Aus $2500) in 2013 from postgraduate research student support (PRSS) scheme 2013, GRS (Graduate Research School) of University of New South Wales, Australia.
CLINAM 2013 fellowship for attending the European Summit for Clinical Nanomedicine and Targeted medicine from antibodies to nanodrugs, diagnostic systems and targeted delivery
Beth Yarrow Memorial Award of UNSW for outstanding research regarding early detection and cure of ovarian cancer in 2013
Publications/Patents
“Albumin bound albendazole for the treatment of cancer and malignant ascites formation”, patent application technical ID No AUS 13_2831, David L Morris, Martina Stenzel, Lubna Hossain, 2013.
“Albendazole encapsulated into pH-responsive nano-sized albumin particles (nab™ technology) aimed for cancer therapy” Lubna Hossain,1, 2, Mohammad H Pourgholami,2 Mingtao Liang,3 Martina Stenzel,1* David L Morris,2
[waiting for the acceptance of the paper in international journal of nanomedicine]
Conference proceedings in clinical Nanomedicine & Targeted Medicine, ‘Delivery of albendazole nanoparticles to the ovarian cancer ; Synthesis to in-vivo study’.